Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-132	-80.6	-36.95	-35.36	-50.64	-42.48
Depreciation & Amortization	0.34	0.32	0.31	0.32	0.33	0.16
Loss (Gain) From Sale of Assets	-	-	-	-	-0	-
Loss (Gain) From Sale of Investments	-2.72	-5.26	-1.84	-0.77	-0.01	0.01
Stock-Based Compensation	7.86	8.8	7.62	6.62	5.47	2.16
Other Operating Activities	-0.26	-0.19	-0.08	-0.05	0.02	-
Change in Accounts Payable	9.36	1.14	-0.4	0.03	-0.97	-3.29
Change in Other Net Operating Assets	20.93	5.03	-2.11	1.64	3.71	1.25
Operating Cash Flow	-96.49	-70.76	-33.46	-27.57	-42.11	-42.2
Capital Expenditures	-0.27	-0.52	-0.16	-0.1	-0.33	-0.06
Cash Acquisitions	-	-	-	-	-	40.64
Investment in Securities	85.78	-84.87	33.52	-90.86	24.5	-23.49
Investing Cash Flow	85.51	-85.39	33.35	-90.96	24.17	17.09
Issuance of Common Stock	65.32	161.88	0.03	75.26	19.89	93.59
Financing Cash Flow	65.32	161.88	0.03	75.26	19.89	93.59
Net Cash Flow	54.34	5.74	-0.08	-43.27	1.95	68.48
Free Cash Flow	-96.76	-71.28	-33.62	-27.67	-42.44	-42.26
Free Cash Flow Per Share	-1.43	-1.16	-0.77	-1.07	-2.47	-3.56
Levered Free Cash Flow	-48.96	-42.05	-20.84	-14.35	-23.09	-23.39
Unlevered Free Cash Flow	-48.96	-42.05	-20.84	-14.35	-23.09	-23.39
Change in Working Capital	30.3	6.18	-2.51	1.67	2.73	-2.04

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q